Altevax SAS

MABDESIGN MEMBER

About us

Altevax is developing an entirely new vaccine technology for cancer and infectious diseases treatement.

Know-how

vaccine development, in-vivo models, phase I, clinical trials

Business offer

Altevax is developing a new class of adjuvant that trigger a strong immune system response against a given tumour target, significantly boosting the antigen effectiveness.

Therapeutic application
  • infectiology
  • immunology
  • oncology

Expertise

  • Pharmacology & Biological activity
  • Therapeutic efficacy
  • Safety
  • Specificity
  • Cell activation
  • Cell-based activation (APCs, AAPCs)
  • Proof of concept
  • in-vivo models
  • Phase I
  • Phase II

Category

  • Therapeutic product

Contact